Marina joined Nouscom in 2016 as the Chief Operating Officer from Versant Ventures where was an Operating Principal.
Prior to Versant, Marina was at Novartis Pharma in Basel in various senior development and commercial roles. As the Global Commercial Head, Near Patient Testing Unit, she developed the global strategy for a point of care diagnostics platform. Her experience in molecular diagnostics extends to In Vitro Diagnostics where she led development of a Companion Diagnostics for RYDAPT™ (midostaurin), the first approved AML drug in over 3 decades. She managed the Global Neurodegeneration portfolio for Novartis driving her Brands to a blockbuster status.
Marina spent 5 years with McKinsey & Company in Chicago, working with Healthcare Fortune 500 companies.
Marina received her PhD in Chemistry from Yale University. She authored peer reviewed publications in the area if HIV/AIDS research.